Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESILIENCE study of ensitrelvir for prevention of long COVID symptoms
jRCTs051230184Active, not recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Ensitrelvir with Placebo (2 arms). Primary endpoint: Composite long COVID symptom persistence at 3 months. Started Feb 2024; status: active, not recruiting.
02
Drugs
ensitrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCTs051230184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051230184.